NanoString Technologies Inc (NSTG)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:NanoString Technologies Inc (NSTG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014008
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NanoString Technologies Inc (NanoString) is a provider of life science products and tools for translational research and molecular diagnostics. The company’s products portfolio includes sprint profiler, Dx analysis system with flex, MAX analysis system, protein assays, solid tumor assays, gene fusion panels, RNA panels, DNA assays, immunology panel, gene expression codesets, pancancer immune profiling and pathways among others. NanoString’s nCounter analysis system provides cost-effective method to profile hundreds of miRNA, miRGE or DNA molecules simultaneously employing digital molecular barcoding technology. The company sells its products through direct sales force and distributors in the US, Europe, the Middle East and Asia-Pacific. NanoString is headquartered in Seattle, Washington, the US.

NanoString Technologies Inc (NSTG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
NanoString Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
NanoString Technologies Inc, Medical Devices Deals, 2011 to YTD 2017 10
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
NanoString Technologies Raises US$0.2 Million In Venture Financing 13
NanoString Technologies Raises US$15 Million In Series E Financing 14
NanoString Technologies To Raise US$0.65 Million In Venture Financing 16
NanoString Technologies Secures US$20 Million In Series D Financing 17
NanoString Technologies Secures US$2.5 Million In Venture Financing 18
Partnerships 19
NanoString Technologies Enters into Agreement with OHSU Knight Cancer Institute 19
NanoString Enters into Research Agreement with CITN for Novel Cancer Immunotherapies 20
NanoString Enters into Co-Development Agreement with Celgene 21
NanoString Technologies And BD Biosciences Enter Into Agreement To Develop Single Cell Isolation And Analysis Workflow 22
Licensing Agreements 23
NanoString Technologies Enters Into Option For Licensing Agreement With Massachusetts General Hospital 23
Equity Offering 24
NanoString Technologies Plans to Raise USD100 Million in Public Offering of Shares 24
NanoString Technologies Completes Public Offering Of Shares For US$55 Million 25
NanoString Technologies Completes IPO Of Shares For US$54 Million 27
NanoString Technologies Inc – Key Competitors 29
NanoString Technologies Inc – Key Employees 30
NanoString Technologies Inc – Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Financial Announcements 32
May 04, 2017: NanoString Technologies Releases Operating Results for First Quarter of 2017 32
Mar 01, 2017: NanoString Technologies Releases Fourth Quarter and Full Year 2016 Operating Results and Provides 2017 Outlook 33
Jan 10, 2017: NanoString Technologies Provides Preliminary Operational and Financial Results for 2016 34
Nov 02, 2016: NanoString Technologies Releases Operating Results for Third Quarter of 2016 35
Aug 03, 2016: NanoString Technologies Releases Operating Results for Second Quarter of 2016 36
May 05, 2016: NanoString Technologies Releases Operating Results for First Quarter of 2016 37
Feb 29, 2016: NanoString Technologies Releases Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Outlook 38
Jan 10, 2016: NanoString Technologies Provides Preliminary Operational and Financial Results for 2015 40
Corporate Communications 41
May 10, 2017: NanoString Appoints Elisha W. Finney to Board of Directors 41
Sep 13, 2016: NanoString Technologies Appoints Kirk Malloy, Ph.D. to Board of Directors 42
Product News 43
Oct 19, 2016: NanoString Technologies Presents Update on Hyb & Seq Next-Generation Sequencing Chemistry at ASHG Annual Meeting 43
Apr 03, 2017: Digital Spatial Profiling Technology Enables Quantitative Protein Profiling in FFPE Tissue Providing Detailed Molecular Characterization of Immune Response to Tumors 45
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
NanoString Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
NanoString Technologies Inc, Deals By Therapy Area, 2011 to YTD 2017 9
NanoString Technologies Inc, Medical Devices Deals, 2011 to YTD 2017 10
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
NanoString Technologies Raises US$0.2 Million In Venture Financing 13
NanoString Technologies Raises US$15 Million In Series E Financing 14
NanoString Technologies To Raise US$0.65 Million In Venture Financing 16
NanoString Technologies Secures US$20 Million In Series D Financing 17
NanoString Technologies Secures US$2.5 Million In Venture Financing 18
NanoString Technologies Enters into Agreement with OHSU Knight Cancer Institute 19
NanoString Enters into Research Agreement with CITN for Novel Cancer Immunotherapies 20
NanoString Enters into Co-Development Agreement with Celgene 21
NanoString Technologies And BD Biosciences Enter Into Agreement To Develop Single Cell Isolation And Analysis Workflow 22
NanoString Technologies Enters Into Option For Licensing Agreement With Massachusetts General Hospital 23
NanoString Technologies Plans to Raise USD100 Million in Public Offering of Shares 24
NanoString Technologies Completes Public Offering Of Shares For US$55 Million 25
NanoString Technologies Completes IPO Of Shares For US$54 Million 27
NanoString Technologies Inc, Key Competitors 29
NanoString Technologies Inc, Key Employees 30

★海外企業調査レポート[NanoString Technologies Inc (NSTG)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Greenyard NV:企業の戦略・SWOT・財務分析
    Greenyard NV - Strategy, SWOT and Corporate Finance Report Summary Greenyard NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Mitsubishi Logistics Corporation
    Mitsubishi Logistics Corporation - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Logistics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Sunesis Pharmaceuticals Inc (VIRX):企業の財務・戦略的SWOT分析
    Sunesis Pharmaceuticals Inc (VIRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Cook Medical Inc:企業の戦略的SWOT分析
    Cook Medical Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Cofidis Participations S.A.:企業の戦略・SWOT・財務分析
    Cofidis Participations S.A. - Strategy, SWOT and Corporate Finance Report Summary Cofidis Participations S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Cadence Biomedical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Cadence Biomedical Inc (Cadence), formerly Empowering Engineering Technologies Corp is a medical device company that provides mobility products. The company offers product such as Kickstart walking system. Its product allows users to regain the ability and endurance to stand, walk and return …
  • JACCS Co Ltd:企業の戦略・SWOT・財務分析
    JACCS Co Ltd - Strategy, SWOT and Corporate Finance Report Summary JACCS Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Orthofix Medical Inc (OFIX):企業の財務・戦略的SWOT分析
    Orthofix Medical Inc (OFIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • International Drug Development Institute-製薬・医療分野:企業M&A・提携分析
    Summary International Drug Development Institute (IDDI) is a healthcare institute that offers clinical data collection, analysis, trial design and trial reporting services. The institute offers biostatistical services and eClinical services and risk-based monitoring programs. Its biostatistical and …
  • Polpharma SA-製薬・医療分野:企業M&A・提携分析
    Summary Polpharma SA (Polpharma) undertakes the research, manufacture and marketing of generic drugs, prescription drugs and over the counter medications. It provides drugs in cardiology, gastroenterology and neurology areas. The company also manufactures over the counter (OTC) medications, dietary …
  • A. Menarini Industrie Farmaceutiche Riunite Srl:企業の戦略的SWOT分析
    A. Menarini Industrie Farmaceutiche Riunite Srl - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competito …
  • Banco Pan SA (BPAN4):企業の財務・戦略的SWOT分析
    Banco Pan SA (BPAN4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Sonoma Pharmaceuticals Inc (OCLS):企業の財務・戦略的SWOT分析
    Summary Sonoma Pharmaceuticals Inc (Sonoma), formerly Oculus Innovative Sciences, is a pharmaceutical company that develops, manufactures and markets prescription and non-prescription products for the treatment of dermatological conditions and advanced tissue care. The company offers products for ad …
  • Parker Drilling Co (PKD):企業の財務・戦略的SWOT分析
    Parker Drilling Co (PKD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • The Pep BoysManny, Moe & Jack:企業の戦略・SWOT・財務分析
    The Pep BoysManny, Moe & Jack - Strategy, SWOT and Corporate Finance Report Summary The Pep BoysManny, Moe & Jack - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • China National Petroleum Corp:電力:M&Aディール及び事業提携情報
    Summary China National Petroleum Corp (CNPC) is an integrated energy company. Its businesses cover oil and gas exploration and development, refining and chemicals, marketing and trading, pipeline transmission and stockpiling, technical services, engineering construction, equipment manufacturing, fin …
  • MVV Energie AG:企業の戦略・SWOT・財務情報
    MVV Energie AG - Strategy, SWOT and Corporate Finance Report Summary MVV Energie AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • LA DORIA S.p.A.:企業の戦略・SWOT・財務情報
    LA DORIA S.p.A. - Strategy, SWOT and Corporate Finance Report Summary LA DORIA S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • GrowMax Resources Corp (GRO):石油・ガス:M&Aディール及び事業提携情報
    Summary GrowMax Resources Corp (GrowMax), formerly Americas Petrogas Inc is an oil and gas company that offers exploration and development of conventional and unconventional oil and gas properties in Argentina. The company explores and develops phosphate and potassium-rich brine resources in northwe …
  • Tsumura & co (4540):製薬・医療:M&Aディール及び事業提携情報
    Summary Tsumura & co (Tsumura) is a traditional pharmaceutical products company, which undertakes the manufacturing and sale of Kampo extract intermediates and granular Kampo formulations. Its product portfolio includes a range of prescription Kampo products, other pharmaceuticals, over-the-counter …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆